Korean J Radiol.  2019 Jan;20(1):5-17. 10.3348/kjr.2018.0040.

What Is New in the 2017 World Health Organization Classification and 8th American Joint Committee on Cancer Staging System for Pancreatic Neuroendocrine Neoplasms?

• Choe J
• Kim KW
• Kim HJ
• Kim DW
• Kim KP
• Hong SM
• Ryu JS
• Tirumani S
• Krajewski
• Ramaiya N

• KMID: 2429916
• DOI: http://doi.org/10.3348/kjr.2018.0040

Abstract

The diagnosis and management of pancreatic neuroendocrine neoplasms (NENs) have evolved significantly in recent years. There are several diagnostic and therapeutic challenges and controversies regarding the management of these lesions. In this review, we focus on the recent significant changes and controversial issues regarding the diagnosis and management of NENs and discuss the role of imaging in the multidisciplinary team approach.

Keyword

Pancreas; Neuroendocrine tumor; NET; Staging; Management; Multidisciplinary

MeSH Terms

Diagnosis
Global Health*
Joints*
Neoplasm Staging*
Neuroendocrine Tumors
Pancreas
World Health Organization*

Figure

• 

  Fig. 1 Stepwise management of pancreatic NENs.Revised from 2017 National Comprehensive Cancer Network guidelines.A. NET. B. NEC. NEC = neuroendocrine carcinomas, NENs = neuroendocrine neoplasms, NET = neuroendocrine tumor, RT = radiation therapy

• 

  Fig. 2 Imaging spectrum of pancreatic NENs according to histologic grade.A. Low-grade NET is generally small-sized and has well-defined margins on imaging (arrow). B. Higher-grade NET is likely to be larger or more frequently show necrotic change (arrow). C. NEC shows less enhancement than NET, and presents as iso-enhancing or hypoenhancing mass in pancreas. Margin of NEC may be less well demarcated than that of NET (arrow).

• 

  Fig. 3 Grade 1 NET in 42-year-old man.A. 2.9-cm, arterial enhancing hypervascular mass in tail of pancreas was found on initial contrast-enhanced CT (arrows). B. After seven years, hypervascular mass in tail of pancreas had increased in size (arrow) and there was new hypervascular mass in liver (arrowheads), suggestive of hepatic metastasis. Fluid collection and peripancreatic infiltration were also present because of secondary pancreatitis. C. On 18F-FDG PET/CT, tumors showed negative or weak uptake. D. PET/CT with 68gallium-labeled somatostatin analog revealed 3.3-cm mass with markedly increased uptake (maximum standard uptake value, 40.6) in tail of pancreas (arrow), other foci in body of pancreas, and additional hepatic masses (arrowheads) with increased uptake, suggesting multifocal NET with overexpression of somatostatin receptor. Physiologic uptake was seen in both adrenal glands. E. Patient underwent transarterial embolization for management of hepatic metastases and arteriography showed hypervascular mass in right portion of liver. CT = computed tomography, FDG = fluorodeoxyglucose, PET = positron-emission tomography F. On histologic specimens (× 100) obtained during liver biopsy, tumor appeared to have relatively uniform and round nuclei with abundant cytoplasmic granules on H&E staining, low Ki-67 index (1.5%), and diffuse positivity on synaptophysin and chromogranin staining. These imaging and histologic findings suggested morphologically well-differentiated NET. H&E = hematoxylin and eosin

• 

  Fig. 4 Grade 3 NEC in 41-year-old woman.This patient was referred to our hospital with tentative diagnosis of ductal carcinoma of pancreas.A. Magnetic resonance cholangiopancreatography showed abrupt tapering of intrapancreatic common bile duct with diffuse upstream dilatation. B. Contrast-enhanced CT showed 2.5-cm, relatively well-defined, low attenuating solid mass in head of pancreas. C. Tumor showed high FDG avidity on FDG-PET. Imaging reports suggested possibility of NEC as well as ductal adenocarcinoma of pancreas, indicating need for biopsy. D. H&E staining (× 40) revealed small, round, blue cells in tumor. Immunohistochemistry specimens (× 40) showed positivity on synaptophysin (E) and Ki-67 (F) staining with Ki-67 proliferation index of 70%. These findings confirmed diagnosis of NEC.

• 

  Fig. 5 Atypical imaging findings in patients with pancreatic NENs.A. Intraductal growth in 42-year-old woman. Axial contrast-enhanced CT scan shows large mass (arrow on left) with intraductal growth causing diffuse dilatation of bile duct upstream (arrows on right). First differential diagnosis was invasive cancer arising from intraductal papillary mucinous neoplasm. However, lesion was confirmed to be grade 3 NEC after surgical resection. B. Cystic change in 48-year-old man. Axial contrast-enhanced CT image shows 5.6-cm cystic lesion with relatively thick wall in tail of pancreas. Preoperative imaging diagnosis was pseudocyst or cystic neoplasm of pancreas. However, surgical specimen confirmed that lesion was grade 1 NET with cystic change. C. Vascular invasion with tumor thrombus in 29-year-old man. Axial contrast-enhanced CT image shows large heterogeneous attenuating mass involving body and tail of pancreas and left para-aortic area (arrowhead). Vascular invasion is apparent and there is tumor thrombus extending into splenoportal confluence (arrow). Biopsy confirmed diagnosis of grade 3 NEC.

• 

  Fig. 6 Discrepancy in determining resectability between imaging and surgery.A. Contrast-enhanced axial CT scan in 48-year-old man with NET in body of pancreas. Scan shows 5-cm mass (arrow) distortion of contour of main portal vein because of circumferential contact between tumor and portal vein of more than 180 degrees (arrowheads). These CT findings may suggest vessel invasion and indicate unresectability. B. Surgical specimen. Exploratory surgery in this patient confirmed that tumor was resectable in that main portal vein was severely compressed by tumor but without apparent vessel invasion. Therefore, distal pancreatectomy and splenectomy were performed. Gross specimen showed well-defined, ovoid soft-tissue mass (M) in body of pancreas but without vessel invasion.

Reference

1. Singhi AD, Klimstra DS. Well-differentiated pancreatic neuroendocrine tumours (PanNETs) and poorly differentiated pancreatic neuroendocrine carcinomas (PanNECs): concepts, issues and a practical diagnostic approach to high-grade (G3) cases. Histopathology. 2018; 72:168–177. PMID: 29239037.

2. Lawrence B, Gustafsson BI, Chan A, Svejda B, Kidd M, Modlin IM. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am. 2011; 40:1–18. PMID: 21349409.

3. Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO classification of tumours of the digestive system. 4th ed. Lyon: International Agency for Research on Cancer;2010.

4. Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas. 2010; 39:707–712. PMID: 20664470.

5. Edge S, Byrd DR, Compton CC, Fritz AG, Greene F, Trotti A. AJCC cancer staging manual. 7th ed. New York, NY: Springer;2010. p. 181–190.

6. Rindi G, Klöppel G, Alhman H, Caplin M, Couvelard A, de Herder WW, et al. all other Frascati Consensus Conference participants. European Neuroendocrine Tumor Society (ENETS). TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2006; 449:395–401. PMID: 16967267.

7. Klimstra DS, Modlin IR, Adsay NV, Chetty R, Deshpande V, Gönen M, et al. Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set. Am J Surg Pathol. 2010; 34:300–313. PMID: 20118772.

8. Klöppel G, Couvelard A, Perren A, Komminoth P, McNicol AM, Nilsson O, et al. Mallorca Consensus Conference participants. European Neuroendocrine Tumor Society. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification. Neuroendocrinology. 2009; 90:162–166. PMID: 19060454.

9. NCCN clinical practice guidelines in oncology. Neuroendocrine tumors. Version 3. National Comprehensive Cancer Network Web site. Accessed December 16, 2017. https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf Published June 13, 2017.

10. Lloyd RV, Osamura RY, Klöppel G, Rosai J. WHO classification of tumours of endocrine organs. 4th ed. Lyon: International Agency for Research on Cancer;2017. p. 209–240.

11. Basturk O, Yang Z, Tang LH, Hruban RH, Adsay V, McCall CM, et al. The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms. Am J Surg Pathol. 2015; 39:683–690. PMID: 25723112.

12. Adsay NV, Bagci P, Tajiri T, Oliva I, Ohike N, Balci S, et al. Pathologic staging of pancreatic, ampullary, biliary, and gallbladder cancers: pitfalls and practical limitations of the current AJCC/UICC TNM staging system and opportunities for improvement. Semin Diagn Pathol. 2012; 29:127–141. PMID: 23062420.

13. Rindi G, Falconi M, Klersy C, Albarello L, Boninsegna L, Buchler MW, et al. TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study. J Natl Cancer Inst. 2012; 104:764–777. PMID: 22525418.

14. Li X, Gou S, Liu Z, Ye Z, Wang C. Assessment of the American Joint Commission on Cancer 8th Edition Staging System for patients with pancreatic neuroendocrine tumors: a surveillance, epidemiology, and end results analysis. Cancer Med. 2018; 7:626–634. PMID: 29380547.

15. Luo G, Javed A, Strosberg JR, Jin K, Zhang Y, Liu C, et al. Modified staging classification for pancreatic neuroendocrine tumors on the basis of the American Joint Committee on Cancer and European Neuroendocrine Tumor Society systems. J Clin Oncol. 2017; 35:274–280. PMID: 27646952.

16. Bushnell DL Jr, O'Dorisio TM, O'Dorisio MS, Menda Y, Hicks RJ, Van Cutsem E, et al. 90Y-edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol. 2010; 28:1652–1659. PMID: 20194865.

17. Ramage JK, Ahmed A, Ardill J, Bax N, Breen DJ, Caplin ME, et al. UK and Ireland Neuroendocrine Tumour Society. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut. 2012; 61:6–32. PMID: 22052063.

18. Reid MD, Balci S, Saka B, Adsay NV. Neuroendocrine tumors of the pancreas: current concepts and controversies. Endocr Pathol. 2014; 25:65–79. PMID: 24430597.

19. Raj N, Valentino E, Capanu M, Tang LH, Basturk O, Untch BR, et al. Treatment response and outcomes of grade 3 pancreatic neuroendocrine neoplasms based on morphology: well differentiated versus poorly differentiated. Pancreas. 2017; 46:296–301. PMID: 27759713.

20. Burns WR, Edil BH. Neuroendocrine pancreatic tumors: guidelines for management and update. Curr Treat Options Oncol. 2012; 13:24–34. PMID: 22198808.

21. Parekh JR, Wang SC, Bergsland EK, Venook AP, Warren RS, Kim GE, et al. Lymph node sampling rates and predictors of nodal metastasis in pancreatic neuroendocrine tumor resections: the UCSF experience with 149 patients. Pancreas. 2012; 41:840–844. PMID: 22781907.

22. Hill JS, McPhee JT, McDade TP, Zhou Z, Sullivan ME, Whalen GF, et al. Pancreatic neuroendocrine tumors: the impact of surgical resection on survival. Cancer. 2009; 115:741–751. PMID: 19130464.

23. Kim KW, Krajewski KM, Nishino M, Jagannathan JP, Shinagare AB, Tirumani SH, et al. Update on the management of gastroenteropancreatic neuroendocrine tumors with emphasis on the role of imaging. AJR Am J Roentgenol. 2013; 201:811–824. PMID: 24059370.

24. Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. NETTER-1 Trial Investigators. Phase 3 trial of ¹⁷⁷Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017; 376:125–135. PMID: 28076709.

25. Villard L, Romer A, Marincek N, Brunner P, Koller MT, Schindler C, et al. Cohort study of somatostatin-based radiopeptide therapy with [(90)Y-DOTA]-TOC versus [(90)Y-DOTA]-TOC plus [(177)Lu-DOTA]-TOC in neuroendocrine cancers. J Clin Oncol. 2012; 30:1100–1106. PMID: 22393097.

26. Terashima T, Morizane C, Hiraoka N, Tsuda H, Tamura T, Shimada Y, et al. Comparison of chemotherapeutic treatment outcomes of advanced extrapulmonary neuroendocrine carcinomas and advanced small-cell lung carcinoma. Neuroendocrinology. 2012; 96:324–332. PMID: 22572060.

27. Sundstrøm S, Bremnes RM, Kaasa S, Aasebø U, Hatlevoll R, Dahle R, et al. Norwegian Lung Cancer Study Group. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up. J Clin Oncol. 2002; 20:4665–4672. PMID: 12488411.

28. Kim DW, Kim HJ, Kim KW, Byun JH, Song KB, Kim JH, et al. Neuroendocrine neoplasms of the pancreas at dynamic enhanced CT: comparison between grade 3 neuroendocrine carcinoma and grade 1/2 neuroendocrine tumour. Eur Radiol. 2015; 25:1375–1383. PMID: 25465713.

29. Takumi K, Fukukura Y, Higashi M, Ideue J, Umanodan T, Hakamada H, et al. Pancreatic neuroendocrine tumors: correlation between the contrast-enhanced computed tomography features and the pathological tumor grade. Eur J Radiol. 2015; 84:1436–1443. PMID: 26022520.

30. Kim C, Byun JH, Hong SM, An S, Kim JH, Lee SS, et al. A comparison of enhancement patterns on dynamic enhanced CT and survival between patients with pancreatic neuroendocrine tumors with and without intratumoral fibrosis. Abdom Radiol (NY). 2017; 42:2835–2842. PMID: 28624923.

31. Cappelli C, Boggi U, Mazzeo S, Cervelli R, Campani D, Funel N, et al. Contrast enhancement pattern on multidetector CT predicts malignancy in pancreatic endocrine tumours. Eur Radiol. 2015; 25:751–759. PMID: 25447971.

32. Rust E, Hubele F, Marzano E, Goichot B, Pessaux P, Kurtz JE, et al. Nuclear medicine imaging of gastro-entero-pancreatic neuroendocrine tumors. The key role of cellular differentiation and tumor grade: from theory to clinical practice. Cancer Imaging. 2012; 12:173–184. PMID: 22743056.

33. Lewis RB, Lattin GE Jr, Paal E. Pancreatic endocrine tumors: radiologic-clinicopathologic correlation. Radiographics. 2010; 30:1445–1464. PMID: 21071369.

34. Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med. 2007; 48:508–518. PMID: 17401086.

35. Haug AR, Auernhammer CJ, Wängler B, Schmidt GP, Uebleis C, Göke B, et al. 68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors. J Nucl Med. 2010; 51:1349–1356. PMID: 20720050.

36. Sharma P, Singh H, Bal C, Kumar R. PET/CT imaging of neuroendocrine tumors with (68)Gallium-labeled somatostatin analogues: an overview and single institutional experience from India. Indian J Nucl Med. 2014; 29:2–12. PMID: 24591775.

37. Gallotti A, Johnston RP, Bonaffini PA, Ingkakul T, Deshpande V, Fernández-del Castillo C, et al. Incidental neuroendocrine tumors of the pancreas: MDCT findings and features of malignancy. AJR Am J Roentgenol. 2013; 200:355–362. PMID: 23345357.

38. Singhi AD, Chu LC, Tatsas AD, Shi C, Ellison TA, Fishman EK, et al. Cystic pancreatic neuroendocrine tumors: a clinicopathologic study. Am J Surg Pathol. 2012; 36:1666–1673. PMID: 23073325.

39. Lee JH, Byun JH, Kim JH, Lee SS, Kim HJ, Lee MG. Solid pancreatic tumors with unilocular cyst-like appearance on CT: differentiation from unilocular cystic tumors using CT. Korean J Radiol. 2014; 15:704–711. PMID: 25469081.

40. Shi C, Siegelman SS, Kawamoto S, Wolfgang CL, Schulick RD, Maitra A, et al. Pancreatic duct stenosis secondary to small endocrine neoplasms: a manifestation of serotonin production? Radiology. 2010; 257:107–114. PMID: 20713615.

41. Lam KY, Lo CY. Pancreatic endocrine tumour: a 22-year clinico-pathological experience with morphological, immunohistochemical observation and a review of the literature. Eur J Surg Oncol. 1997; 23:36–42. PMID: 9066745.

42. Volante M, Righi L, Berruti A, Rindi G, Papotti M. The pathological diagnosis of neuroendocrine tumors: common questions and tentative answers. Virchows Arch. 2011; 458:393–402. PMID: 21344263.

43. Balachandran A, Tamm EP, Bhosale PR, Katz MH, Fleming JB, Yao JC, et al. Venous tumor thrombus in nonfunctional pancreatic neuroendocrine tumors. AJR Am J Roentgenol. 2012; 199:602–608. PMID: 22915400.

44. Kulke MH, Siu LL, Tepper JE, Fisher G, Jaffe D, Haller DG, et al. Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute neuroendocrine tumor clinical trials planning meeting. J Clin Oncol. 2011; 29:934–943. PMID: 21263089.

45. Oberg K, Casanovas O, Castaño JP, Chung D, Delle Fave G, Denèfle P, et al. Molecular pathogenesis of neuroendocrine tumors: implications for current and future therapeutic approaches. Clin Cancer Res. 2013; 19:2842–2849. PMID: 23459719.

46. Kim JH, Lee JM, Park JH, Kim SC, Joo I, Han JK, et al. Solid pancreatic lesions: characterization by using timing bolus dynamic contrast-enhanced MR imaging assessment--a preliminary study. Radiology. 2013; 266:185–196. PMID: 23192779.

47. Bali MA, Metens T, Denolin V, Delhaye M, Demetter P, Closset J, et al. Tumoral and nontumoral pancreas: correlation between quantitative dynamic contrast-enhanced MR imaging and histopathologic parameters. Radiology. 2011; 261:456–466. PMID: 21852570.

48. Hwang EJ, Lee JM, Yoon JH, Kim JH, Han JK, Choi BI, et al. Intravoxel incoherent motion diffusion-weighted imaging of pancreatic neuroendocrine tumors: prediction of the histologic grade using pure diffusion coefficient and tumor size. Invest Radiol. 2014; 49:396–402. PMID: 24500090.

49. Koh DM, Collins DJ, Orton MR. Intravoxel incoherent motion in body diffusion-weighted MRI: reality and challenges. AJR Am J Roentgenol. 2011; 196:1351–1361. PMID: 21606299.

50. De Cecco CN, Darnell A, Rengo M, Muscogiuri G, Bellini D, Ayuso C, et al. Dual-energy CT: oncologic applications. AJR Am J Roentgenol. 2012; 199(5 Suppl):S98–S105. PMID: 23097174.

51. Kartalis N, Mucelli RM, Sundin A. Recent developments in imaging of pancreatic neuroendocrine tumors. Ann Gastroenterol. 2015; 28:193–202. PMID: 25830417.